Header Logo

Connection

Hung Tseng to Vaccination

Back to Details
This is a "connection" page, showing publications Hung Tseng has written about Vaccination.
Hung Tseng
Connection Strength
4.960
Vaccination
  1. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model. J Manag Care Spec Pharm. 2020 Dec; 26(12):1567-1575.
    View in: PubMed
    Score: 0.475
  2. Safety of MenACWY-CRM vaccine exposure during pregnancy. Vaccine. 2020 03 10; 38(12):2683-2690.
    View in: PubMed
    Score: 0.453
  3. Impact of the change of copay policy in Medicare Part D on zoster vaccine uptake among Medicare beneficiaries in a managed care organization. BMC Health Serv Res. 2017 07 21; 17(1):503.
    View in: PubMed
    Score: 0.380
  4. Zoster Vaccine and the Risk of Postherpetic Neuralgia in Patients Who Developed Herpes Zoster Despite Having Received the Zoster Vaccine. J Infect Dis. 2015 Oct 15; 212(8):1222-31.
    View in: PubMed
    Score: 0.327
  5. Vaccines and the risk of multiple sclerosis and other central nervous system demyelinating diseases. JAMA Neurol. 2014 Dec; 71(12):1506-13.
    View in: PubMed
    Score: 0.316
  6. Hepatitis B testing and vaccination among adults with sexually transmitted infections in a large managed care organization. Clin Infect Dis. 2014 Jun; 58(12):1739-45.
    View in: PubMed
    Score: 0.300
  7. Differences in influenza vaccination coverage by race and ethnicity across age groups in the Vaccine Safety Datalink, 2017-18 through 2022-23 influenza seasons. Vaccine. 2025 Oct 03; 64:127667.
    View in: PubMed
    Score: 0.167
  8. Respiratory syncytial virus vaccine uptake among adults aged =60?years in a large, integrated healthcare system in Southern California 2023-2024. Vaccine. 2025 Apr 19; 53:127033.
    View in: PubMed
    Score: 0.162
  9. Comparative Effectiveness of Cell-Based Versus Egg-Based Influenza Vaccines in Prevention of Influenza Hospitalization During the 2022-2023 Season Among Adults 18-64?Years. Influenza Other Respir Viruses. 2024 Dec; 18(12):e70025.
    View in: PubMed
    Score: 0.158
  10. Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults =65 Years of Age. Clin Infect Dis. 2024 Nov 22; 79(5):1283-1292.
    View in: PubMed
    Score: 0.158
  11. COVID-19 Vaccination Coverage and Factors Associated With Vaccine Uptake Among People With HIV. JAMA Netw Open. 2024 Jun 03; 7(6):e2415220.
    View in: PubMed
    Score: 0.153
  12. Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5. Nat Commun. 2023 Jan 12; 14(1):189.
    View in: PubMed
    Score: 0.139
  13. Risk of herpes zoster following mRNA COVID-19 vaccine administration. Expert Rev Vaccines. 2023 Jan-Dec; 22(1):643-649.
    View in: PubMed
    Score: 0.138
  14. Safety of tetanus, diphtheria, acellular pertussis (Tdap) vaccination during pregnancy. Vaccine. 2022 Jul 30; 40(32):4503-4512.
    View in: PubMed
    Score: 0.133
  15. Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study. BMJ. 2021 12 15; 375:e068848.
    View in: PubMed
    Score: 0.129
  16. COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 29; 70(43):1520-1524.
    View in: PubMed
    Score: 0.128
  17. Completion of the two-dose recombinant zoster vaccine series in adults 50 years and older. Vaccine. 2021 02 05; 39(6):926-932.
    View in: PubMed
    Score: 0.121
  18. The Epidemiology of Herpes Zoster in Immunocompetent, Unvaccinated Adults =50 Years Old: Incidence, Complications, Hospitalization, Mortality, and Recurrence. J Infect Dis. 2020 08 04; 222(5):798-806.
    View in: PubMed
    Score: 0.117
  19. Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018. Vaccine. 2019 09 16; 37(39):5807-5811.
    View in: PubMed
    Score: 0.110
  20. Patient report of herpes zoster pain: Incremental benefits of zoster vaccine live. Vaccine. 2019 06 06; 37(26):3478-3484.
    View in: PubMed
    Score: 0.108
  21. Human papillomavirus vaccine series completion in boys before and after recommendation for routine immunization. Vaccine. 2017 02 07; 35(6):897-902.
    View in: PubMed
    Score: 0.092
  22. Declining Effectiveness of Herpes Zoster Vaccine in Adults Aged =60 Years. J Infect Dis. 2016 06 15; 213(12):1872-5.
    View in: PubMed
    Score: 0.086
  23. Risk of Herpes Zoster and Disseminated Varicella Zoster in Patients Taking Immunosuppressant Drugs at the Time of Zoster Vaccination. Mayo Clin Proc. 2015 Jul; 90(7):865-73.
    View in: PubMed
    Score: 0.082
  24. Postlicensure surveillance for pre-specified adverse events following the 13-valent pneumococcal conjugate vaccine in children. Vaccine. 2013 May 24; 31(22):2578-83.
    View in: PubMed
    Score: 0.070
  25. Safety of a tetanus-diphtheria-acellular pertussis vaccine when used off-label in an elderly population. Clin Infect Dis. 2013 Feb; 56(3):315-21.
    View in: PubMed
    Score: 0.069
  26. Signal identification and evaluation for risk of febrile seizures in children following trivalent inactivated influenza vaccine in the Vaccine Safety Datalink Project, 2010-2011. Vaccine. 2012 Mar 02; 30(11):2024-31.
    View in: PubMed
    Score: 0.065
  27. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011 May 09; 29(20):3628-32.
    View in: PubMed
    Score: 0.061
  28. Analysis of factors associated with varicella-zoster virus susceptibility among children 0-12 years old in Taiwan. Med Mal Infect. 2007 Apr; 37(4):222-8.
    View in: PubMed
    Score: 0.046
  29. Mortality risk after COVID-19 vaccination: A self-controlled case series study. Vaccine. 2024 Mar 07; 42(7):1731-1737.
    View in: PubMed
    Score: 0.037
  30. Seroepidemiology study of Japanese encephalitis neutralizing antibodies in southern Taiwan: a comparative study between urban city and country townships. Am J Infect Control. 2003 Nov; 31(7):435-40.
    View in: PubMed
    Score: 0.037
  31. A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. Vaccine. 2023 01 16; 41(3):844-854.
    View in: PubMed
    Score: 0.035
  32. Kawasaki Disease Following the 13-valent Pneumococcal Conjugate Vaccine and Rotavirus Vaccines. Pediatrics. 2022 12 01; 150(6).
    View in: PubMed
    Score: 0.034
  33. The use of natural language processing to identify Tdap-related local reactions at five health care systems in the Vaccine Safety Datalink. Int J Med Inform. 2019 07; 127:27-34.
    View in: PubMed
    Score: 0.027
  34. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
    View in: PubMed
    Score: 0.022
  35. Confounder adjustment in vaccine safety studies: comparing three offset terms for case-centered approach. Vaccine. 2013 Jan 02; 31(2):431-5.
    View in: PubMed
    Score: 0.017
  36. The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan. Vaccine. 2006 Mar 24; 24(14):2669-73.
    View in: PubMed
    Score: 0.011

© 2025 Kaiser Permanente

Your Privacy Choices